Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.
暂无分享,去创建一个
H. Uno | S. Solomon | M. Pfeffer | Lee-Jen Wei | T. Cai | J. Wittes | H. Fu | B. Claggett | L. Tian | S. Evans | Lu Tian
[1] Lihui Zhao,et al. Predicting the restricted mean event time with the subject's baseline covariates in survival analysis. , 2014, Biostatistics.
[2] A. Katz,et al. Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations , 2013, Diabetes Care.
[3] Yoshiaki Uyama,et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. Raz,et al. Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs , 2011, Diabetes Care.
[5] Erik T. Parner,et al. Regression Analysis of Censored Data Using Pseudo-observations , 2010 .
[6] Miguel A Hernán,et al. The hazards of hazard ratios. , 2010, Epidemiology.
[7] Sanjay Kaul,et al. Non-inferiority study design: lessons to be learned from cardiovascular trials. , 2012, European heart journal.
[8] R. D'Agostino,et al. Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.
[9] J. Schumi,et al. TRIALS REVIEW Open Access , 2022 .
[10] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[11] John P. Klein,et al. SAS and R functions to compute pseudo-values for censored data regression , 2008, Comput. Methods Programs Biomed..
[12] Patrick Royston,et al. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.
[13] William Checkley,et al. Multilevel competing risks in the evaluation of nosocomial infections: time to move on from proportional hazards and even from hazards altogether , 2014, Critical Care.
[14] R. Garrick. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .
[15] L. Kux. OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .
[16] P. Royston,et al. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.
[17] S. Kaul,et al. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. , 2013, The New England journal of medicine.
[18] Lihui Zhao,et al. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study , 2012, Clinical trials.
[19] D. Harrington,et al. Counting Processes and Survival Analysis , 1991 .
[20] Nicky J Welton,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.
[21] L J Wei,et al. Nonparametric estimation for the difference or ratio of median failure times. , 1993, Biometrics.
[22] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[23] S. Solomon,et al. Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.
[24] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[25] David M. Zucker,et al. Restricted Mean Life with Covariates: Modification and Extension of a Useful Survival Analysis Method , 1998 .
[26] Michael Parzen,et al. Simultaneous Confidence Intervals for the Difference of Two Survival Functions , 1997 .
[27] D.,et al. Regression Models and Life-Tables , 2022 .
[28] Lee-Jen Wei,et al. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. , 1992, Statistics in medicine.